Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — FY2025 Earnings Presentation
24 slides from Aft Pharmaceuticals's earnings presentation, May 22, 2025
Slide 1: Investor Presentation FY 2025
INVESTOR PRESENTATION FY 2025 | 22 MAY 2025 Dr Hartley Atkinson Managing Director Malcolm Tubby Chief Financial Officer
Slide 2: Important Notice
Important Notice This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. This presentation should be read in
Slide 3: Agenda
Agenda • Key Highlights • Strategic Initiatives and Pipeline Dr Hartley Atkinson • Financial Results Managing Director • FY26 and LT Outlook • Questions and Answers Malcolm Tubby Chief Financial Officer AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 3
Slide 4: Building the Foundation for the Next Phase of Growth
Building the Foundation for the Next Phase of Growth Fortifying AFT’s Global Network to Address Un-met Need CONTINUED STRENGTH IN EXPANDING GLOBAL FOOTPRINT ESTABLISHED ANZ BUSINESS • Europe: UK & EU • FY 25 Total Sales $208.0M (5yr CAGR 14%) • North America: USA & Canada • ANZ Sales $180.9m • Asia:
Slide 5: Strategic Efforts Continue to Drive Underlying Momentum
Strategic Efforts Continue to Drive Underlying Momentum KEY HIGHLIGHTS • FY26 revenues reach a new record of $208.0 million up 6% over FY 24 following the neutralization of 1H 25 disruption • Double digit growth of product sales and royalty income of $207.4; despite lower license income ($0.7 millio
Slide 6: Inflection Yields a Balance of Growth and Attractive Shareholder Return
Inflection Yields a Balance of Growth and Attractive Shareholder Return • AFT continues to invest in its product pipeline and commercialization to fuel future commercial market traction and overall growth • Despite continued investment, shareholder equity has grown steadily since FY19 • Net debt as
Slide 7: AFT's Global Reach
AFT’s Global Reach Our medicines are now available in nearly 80 countries around the world AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 7
Slide 8: Australia: Improved Market Traction with Product and Sales Investments
Australia: Improved Market Traction with Product and Sales Investments • Revenues in Australia grew 17% to $127.1 million from $108.2 million in FY 24, led by eyecare, pain relief, iron supplements, and the broad portfolio of injectables and prescription. • Growth is primarily driven by increasing m
Slide 9: New Zealand: Growth led by the Pain, Eyecare, Skincare Categories
New Zealand: Growth led by the Pain, Eyecare, Skincare Categories • Revenues in New Zealand grew 10% to $53.8 million, up from $48.7 million in FY 24, led by strength in eyecare, pain relief, dermatology, and the broad portfolio of injectables and prescription. • Operating profit improved to $8.8 mi
Slide 10: Asia: Emerging Inroads into China
Asia: Emerging Inroads into China • Revenues in Asia increased to $11.1 million, up from $10.7 million in FY 24. 1H 25 disruptions to Maxigesic IV sales following the Korean doctors’ strike masks the strong performance in the region. 2H 25 revenue of $6.7 million, up 52% (1H 25 of $4.4 million). • R
Slide 11: International Expansion – Investing for Long Term Growth in New Markets
International Expansion – Investing for Long Term Growth in New Markets INTERNATIONAL REVENUE COUNTRIES WHERE MAXIGESIC IS SOLD AND ORDERED $30.0 $27.8 90 80 $25.0 80 73 70 $20.0 61 $16.0 60 COUNTRIES NZ$M $15.0 $13.1 50 46 $11.7 43 $9.9 40 $10.0 19.3 28 15.4 30 10.8 20 $5.0 20 7.8 6.4 7 9 $0.0 10 3
Slide 12: Expanding AFT's Global Footprint and Scale
Expanding AFT’s Global Footprint and Scale New markets for our proprietary IP and in-licensed new products are approaching breakeven AFT PHARM USA • Selected OTC launches and coordinate licensees and distributors AFT PHARM UK (70% AFT) • Launched Combogesic tablets and IV. Launching multiple product
Slide 13: Progressing Research and Development Investments
Progressing Research and Development Investments Several programs have exited development and are moving to revenue generation COMMERCIALISATION EFFORTS A significant number of licensing agreement discussions underway RESEARCH AND DEVELOPMENT EXPENSES Maxigesic – nine dose forms protected by patents
Slide 14: A Strong Research and Development Pipeline
A Strong Research and Development Pipeline AFT’s positive cashflows have positioned the company well to undertake and secure research and development projects either alone or in partnership with others. PROJECT1 PATENT PARTNERSHIP / APPLICATION Hospital injectables Edge Pharmaceuticals. Injectables
Slide 15: Gross Margin and Operating Profit Offset by Mix Changes and Investment
Gross Margin and Operating Profit Offset by Mix Changes and Investment 2025 Revenue 2024 Revenue Year to 31 March $000 % $000 % ∆% • Gross Margin on product sales and Revenue 208,021 195,411 6% royalties of 43.9% improved by 1 point, driven by the revenue growth in the higher Gross profit 91,713 44.
Slide 16: AFT is Well Funded – Well Positioned to Fund Growth Investments
AFT is Well Funded – Well Positioned to Fund Growth Investments 2025 2024 Year to 31 March $000 $000 ∆% • Net debt at the end of March 2025 was Current assets (excluding cash) 97,232 93,687 $14.5 million down from $16.2 million at the Cash 11,110 12,040 end of FY 24. • Dividend of 1.8 cents per shar
Slide 17: Growth Investment Underpinned by Ongoing Strong Cashflow
Growth Investment Underpinned by Ongoing Strong Cashflow 2025 2024 Year to 31 March $000 $000 ∆% Net cash generated from operating activities 13,178 28,861 (54.3)% • Continued investment into research and Net cash used in investing activities (6,953) (9,527) (27.0)% development projects to fuel long
Slide 18: Outlook: Positioned to Drive Future Growth in Both Revenue and Earnings
Outlook: Positioned to Drive Future Growth in Both Revenue and Earnings • AFT is expecting to extend its growth record in FY 26 and is well positioned to achieve its revenue target of $300 million by the end of FY 27. • Operations scaled and benefitted from the expanding geographical reach and incre
Slide 19: Questions and Answers
QUESTIONS AND ANSWERS
Slide 20: Appendix 1: History of AFT Pharmaceuticals
Appendix 1: History of AFT Pharmaceuticals AFT was founded over 25 years ago by Dr Hartley and Marree Atkinson. Since then, AFT has remained an Atkinson-family controlled business and has grown organically into Australia and internationally The 2015 IPO raised funds to pursue a more aggressive (and
Slide 21: Appendix 2: Australasian Product Portfolio
Appendix 2: Australasian Product Portfolio AFT has the #1 selling product (Maxigesic) in the Australian para-ibu1 combo pain relief. AFT’s portfolio includes a combination of over 150 proprietary, branded and generic products which address the following therapeutic areas: Pain Maxigesic, ParaOsteo,
Slide 22: Appendix 3: AFT Global Product Portfolio
Appendix 3: AFT Global Product Portfolio AFT is building the global presence of its proprietary and patented products through its network of licensees and distributors. It continues the development of its portfolio of repurposed medicines: Maxigesic1, Pascomer, NasoSURF, and Crystaderm Pain Maxigesi
Slide 23: Appendix 4: Reconciliation of EBITDA to GAAP
Appendix 4: Reconciliation of EBITDA to GAAP AFTs standard profit measure prepared under New Zealand GAAP is net profit after tax. AFT has used the non-GAAP profit measure of EBITDA when discussing financial performance in this document. AFT directors and management believe that this measure provide
Slide 24: For More Information
FOR MORE INFORMATION Dr Hartley Atkinson Managing Director Email: hartley.atkinson@aftpharm.com Malcolm Tubby Chief Financial Officer Email: malcolm.tubby@aftpharm.com AFT Pharmaceuticals Limited Level 1, 129 Hurstmere Road Takapuna, Auckland 0622 New Zealand www.aftpharm.com